Cellectar Biosciences, Inc. Net Income (Loss) Attributable to Parent, Diluted
Cellectar Biosciences, Inc. (CLRB) reported Net Income (Loss) Attributable to Parent, Diluted of -$51.87 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-03-04
- Cellectar Biosciences, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2024-12-31 was -$2.36M.
- Cellectar Biosciences, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2024-09-30 was -$16.09M.
- Cellectar Biosciences, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2024-06-30 was -$6.77M.
- Cellectar Biosciences, Inc. net income (loss) attributable to parent, diluted for fiscal 2024 was -$51.87M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month | Net Income (Loss) Attributable to Parent, Diluted 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$18.45M derived: sum of 2 quarters · filed 2026-03-04 | -$25.22M derived: sum of 3 quarters · filed 2026-03-04 | -$51.87M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$16.09M 10-Q · filed 2025-11-13 | -$22.87M derived: sum of 2 quarters · filed 2025-11-13 | -$49.51M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$6.77M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |